UroGen Pharma Ltd.
URGNNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $1.74B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $16.50$50.81
- Volume (live)
- -
- Avg. volume (3M)
- 925.17K
UroGen Pharma (URGN) Stock Price & Financial Analysis
UroGen Pharma Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $33.80 - $35.02 |
|---|---|
| 52-Week High | $50.81 |
| 52-Week Low | $16.50 |
| Open | $34.44 |
| Volume (last close) | 738.10K |
| Average Volume (3M) | 925.17K |
| Revenue (TTM) | 188.73M |
|---|---|
| Net Income (TTM) | -97.64M |
| Free Cash Flow (TTM) | -159.13M |
| EPS (TTM) | −$1.97 |
| Profit Margin | -51.73% |
| Operating Margin | -35.32% |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 1.74B |
|---|---|
| Shares Outstanding | 50.38M |
| Price to Sales (P/S) | 9.21 |
| Price to Book (P/B) | -13.12 |
| EV/EBITDA | -26.37 |
| 50-Day MA | $42.73 |
|---|---|
| 200-Day MA | $30.80 |
| 1-Year Change | +102.83% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
UroGen Pharma at a Glance
As of the Oct 23, 2026 close, UroGen Pharma (URGN) has a market capitalization of $1.74B. The stock trades at 9.2× sales. Over the trailing twelve months it lost $97.64M on revenue of $188.73M and burned $159.13M of free cash flow. Revenue grew 100.3% year over year.
As of its latest reported balance sheet, it holds $79.13M in cash and securities against $190.83M of debt, a net debt position of $111.70M.
UroGen Pharma does not currently pay a dividend.
The share price is up 102.8% over the past year. At $34.49 (the Oct 23, 2026 close) it sits within its 52-week range of $16.50 to $50.81, above its 200-day moving average of $30.80.
Based on 7 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $60.20, 74.5% above the Oct 23, 2026 close.
Frequently Asked Questions About UroGen Pharma
What is the current stock price for URGN?
As of the Oct 23, 2026 close, URGN stock trades at $34.49. The 52-week range is $16.50–$50.81, with a day range of $33.80–$35.02.
What is the P/E ratio for URGN?
The P/E ratio (Price-to-Earnings) for URGN is shown in the Key Statistics section. This valuation metric helps compare UroGen Pharma Ltd. to industry peers.
Does URGN pay dividends?
UroGen Pharma does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for URGN?
Based on ratings from 7 professional analysts over the last 90 days, the consensus for URGN is Buy. The average 12-month price target is $60.20, a 74.5% upside from the Oct 23, 2026 close of $34.49.
What is the market cap of URGN?
As of the Oct 23, 2026 close, UroGen Pharma's market capitalization is $1.74B, classifying it as a small-cap company. UroGen Pharma operates in the Healthcare sector within the Biotechnology industry.